InnoCare Pharma Ltd. (HK:9969) has released an update.
InnoCare Pharma Ltd. has announced the successful results of their Phase II clinical trial for ICP-488, an oral treatment for moderate-to-severe plaque psoriasis, which met its primary endpoint by showing significant improvement in patients. The study reported a substantial number of patients achieving at least a 75% reduction in the Psoriasis Area and Severity Index score after 12 weeks of treatment, with most adverse events being mild or moderate. The company plans to proceed with a Phase III study and explore further applications in other autoimmune diseases.
For further insights into HK:9969 stock, check out TipRanks’ Stock Analysis page.